San Francisco, California, July 17, 2017 :“Tapentadol Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025” is a deep and descriptive investigation of what constitute as the positive and negative aspects of influence for tapentadol, in terms of sales, revenue generated, core regions for analysis, and future scope. The drug was approved by the USFDA in 2008 and has since found an optimistic scope of use as a moderate opioid with an analgesic efficacy nearly similar to oxycodone, while imparting a much smaller list of side effects. One of the key advantages of tapentadol is that it is not a pro-drug and therefore does not have to be metabolized in order to have full effect.
One of the primary drivers impacting the global tapentadol market is the growing number of patients suffering from chronic diseases and the related musculoskeletal pains. Opioids are considered to be one of the top treatments for chronic pains, and tapentadol fills a gap in the pharmaceutical industry for people who have more severe reactions to older opioids, or are unable to fully metabolize them to gain their advantages. Tapentadol is also known to show lower side effects than other members in its group, thereby receiving a greater preference. The efficacy of tapentadol is gauged to be somewhere between that of tramadol and morphine.
However, the global tapentadol market is currently being restrained by its own list of adverse side effects. The drug is linked to loss of physical as well as cognitive abilities if used extensively. It is strongly advised by medical practitioners to avoid handling heavy machinery while on the opioid. Other side effects include CNS sedation, dizziness, constipation, and nausea, and many patients have been recorded to show most of these. Prolonged consumption of tapentadol is also being linked to the elevated risk of seizures, which makes them a risky opioid to be administered to patients suffering from epilepsy.
From a regional perspective, North America is expected to continue leading the global tapentadol market, as it has done over the recent years. The region is known for a heavy presence of the leading players in the pharmaceutical industry, as well as pushing for further research and development through government-granted as well as private investments and incentive schemes. Europe is showing a similar growth pattern, owing to the significantly higher population of geriatric patients in the region.
The leading players in the global tapentadol market so far, have included Johnson & Johnson Pharmaceutical Research & Development, L.L.C., IPCA Laboratories Ltd., Lupin Laboratories Ltd., Ranbaxy Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Cadila Pharmaceuticals Ltd., Tirupati Medicare Ltd, and Manus Aktteva Biopharma LLP.